Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
Reviva Pharmaceuticals announced that CEO Dr. Laxminarayan Bhat will participate in a fireside chat hosted by A.G.P. Equity Research on April 27, 2026. The discussion will focus on the clinical-stage candidate brilaroxazine, highlighting positive topline data from the Phase 3 RECOVER trial in schizophrenia and upcoming regulatory and IP milestones.
Key figures
- Drug Name
- brilaroxazine
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.